Three-Year Outcomes of Patients with Neovascular Age-Related Macular Degeneration Treated with Aflibercept under the National Health Insurance Program in Taiwan

Table 2

Univariate and multivariate analysis for central macular thickness at the third year in the complete 3-year follow-up group (n = 99).

n = 99	Univariate analysis		Multivariate analysis
		value		value
Age	−0.032	0.765	−0.029	0.799
Sex	−0.044	0.685	0.004	0.969
Visual acuity
Baseline	−0.062	0.567
3^rd month	0.028	0.803
1^st year	−0.092	0.401	−0.128	0.276
2^nd year	0	0.999
Central macular thickness (CMT)
Baseline	0.028	0.799
3^rd month	0.306	0.008
1^st year	0.258	0.031	0.341	0.034
2^nd year	0.434	<0.001
3^rd year	0.589	<0.001
Others
SRF at baseline	0.152	0.187
SRF at 1^st year	0.038	0.738	−0.130	−0.238
IRC at baseline	0.175	0.128
IRC at 1^st year	0.374	0.001	0.161	0.275
RPED at baseline	−0.081	0.484
RPED at 1^st year	0.210	0.066	0.021	0.857
Number of injections
1^st year	−0.06	0.578	−0.034	0.765
Total	−0.059	0.586

Statistically significant. SRF, subretinal fluid; IRC, intraretinal cyst; RPED, retinal pigment epithelial detachment.